MX346730B - Composiciones y metodos para el tratamiento de la hipertension pulmonar. - Google Patents

Composiciones y metodos para el tratamiento de la hipertension pulmonar.

Info

Publication number
MX346730B
MX346730B MX2013004190A MX2013004190A MX346730B MX 346730 B MX346730 B MX 346730B MX 2013004190 A MX2013004190 A MX 2013004190A MX 2013004190 A MX2013004190 A MX 2013004190A MX 346730 B MX346730 B MX 346730B
Authority
MX
Mexico
Prior art keywords
methods
pulmonary hypertension
compositions
treatment
formulations
Prior art date
Application number
MX2013004190A
Other languages
English (en)
Other versions
MX2013004190A (es
Inventor
Belardinelli Luiz
Campbell Gillies Hunter
Liang Faquan
Shryock John
Yang Suya
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45939010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346730(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2013004190A publication Critical patent/MX2013004190A/es
Publication of MX346730B publication Critical patent/MX346730B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan formulaciones que comprenden cantidades terapéuticamente efectivas de ambrisentán o una sal farmacéuticamente aceptable del mismo y tadalafil o una sal farmacéuticamente aceptable del mismo y los métodos para tratar y/o prevenir la hipertensión pulmonar mediante la administración de las formulaciones.
MX2013004190A 2010-10-15 2011-10-14 Composiciones y metodos para el tratamiento de la hipertension pulmonar. MX346730B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39352910P 2010-10-15 2010-10-15
US201161490454P 2011-05-26 2011-05-26
US201161497475P 2011-06-15 2011-06-15
PCT/US2011/056404 WO2012051559A2 (en) 2010-10-15 2011-10-14 Compositions and methods of treating pulmonary hypertension

Publications (2)

Publication Number Publication Date
MX2013004190A MX2013004190A (es) 2013-07-29
MX346730B true MX346730B (es) 2017-03-30

Family

ID=45939010

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004190A MX346730B (es) 2010-10-15 2011-10-14 Composiciones y metodos para el tratamiento de la hipertension pulmonar.

Country Status (26)

Country Link
US (3) US20120269898A1 (es)
EP (2) EP2637664B1 (es)
JP (2) JP5806320B2 (es)
KR (2) KR20130069855A (es)
CN (1) CN103458690B (es)
AR (1) AR083422A1 (es)
AU (2) AU2011315891B2 (es)
BR (1) BR112013008983A2 (es)
CA (1) CA2814518C (es)
CY (1) CY1119007T1 (es)
DK (1) DK2637664T3 (es)
EA (2) EA201691759A1 (es)
ES (1) ES2627944T3 (es)
HR (1) HRP20170848T1 (es)
HU (1) HUE033346T2 (es)
LT (1) LT2637664T (es)
MX (1) MX346730B (es)
NZ (2) NZ610012A (es)
PL (1) PL2637664T3 (es)
PT (1) PT2637664T (es)
RS (1) RS56135B1 (es)
SI (1) SI2637664T1 (es)
SM (1) SMT201700297T1 (es)
TW (1) TWI542580B (es)
WO (1) WO2012051559A2 (es)
ZA (1) ZA201302746B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2101777T1 (sl) 2006-12-12 2015-08-31 Gilead Sciences, Inc. Sestavek za zdravljenje pljučne hipertenzije
JP5806320B2 (ja) 2010-10-15 2015-11-10 ギリアード サイエンシーズ， インコーポレイテッド 肺高血圧症を処置するための組成物および方法
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014174529A2 (en) * 2013-04-23 2014-10-30 Hetero Research Foundation Polymorphs of avanafil
WO2015069839A1 (en) * 2013-11-06 2015-05-14 Gilead Sciences, Inc. Combination therapy for treating pulmonary hypertension
CN105581990A (zh) * 2014-08-27 2016-05-18 人福医药集团股份公司 安立生坦片剂及其制备方法
CA2982436C (en) * 2015-03-13 2023-09-12 Indiana University Research And Technology Corporation Targeting cgmp-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods
RU2748278C2 (ru) 2016-07-15 2021-05-21 Акселерон Фарма Инк. Композиции и способы лечения легочной гипертензии
KR20230093341A (ko) * 2016-10-27 2023-06-27 풀모킨 인코포레이티드 폐고혈압을 치료하기 위한 병용 요법
WO2019010445A1 (en) * 2017-07-07 2019-01-10 The Regents Of The University Of Colorado, A Body Corporate COMPOSITIONS AND METHOD FOR THE TREATMENT OF PULMONARY HYPERTENSION
BR112020012986A2 (pt) * 2017-12-26 2020-12-01 Ftf Pharma Private Limited formulações orais líquidas para inibidores de pde v
CN109406688A (zh) * 2018-09-28 2019-03-01 中国食品药品检定研究院 用于检测产品中违禁药品的标准样品
EP4065119B1 (en) 2019-11-29 2024-09-04 Actelion Pharmaceuticals Ltd Initial triple combination therapy with macitentan, tadalafil, and selexipag for treating pulmonary arterial hypertension
EP4076398B1 (en) 2019-12-16 2026-02-18 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hf-pef)
KR102606504B1 (ko) * 2020-04-10 2023-11-29 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
CN112826944B (zh) * 2021-01-29 2023-08-15 台州职业技术学院 一种安立生坦包合物及其制备方法
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
EP4684777A1 (en) 2024-07-24 2026-01-28 Adalvo Limited A fixed-dose pharmaceutical composition comprising (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid and (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino{1',2:1,6]pyrido[3,4-b]indole-1,4-dione

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
NZ504436A (en) 1997-11-12 2001-08-31 Bayer Ag 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
CA2572179A1 (en) 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
CN101072564A (zh) * 2004-08-26 2007-11-14 恩希赛弗制药公司 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途
CN101454320B (zh) 2006-04-21 2012-12-19 辉瑞产品公司 吡啶并[3，4-b]吡嗪酮
WO2008073927A1 (en) * 2006-12-12 2008-06-19 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
SI2101777T1 (sl) 2006-12-12 2015-08-31 Gilead Sciences, Inc. Sestavek za zdravljenje pljučne hipertenzije
MX2010001255A (es) 2007-07-31 2010-12-06 Gilead Colorado Inc Metabolitos y derivados de ambrisentan.
WO2010062640A1 (en) 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications
JP5806320B2 (ja) 2010-10-15 2015-11-10 ギリアード サイエンシーズ， インコーポレイテッド 肺高血圧症を処置するための組成物および方法

Also Published As

Publication number Publication date
US9549926B2 (en) 2017-01-24
MX2013004190A (es) 2013-07-29
AU2011315891B2 (en) 2015-08-13
WO2012051559A3 (en) 2013-10-17
EP2637664B1 (en) 2017-03-29
ES2627944T3 (es) 2017-08-01
CN103458690A (zh) 2013-12-18
TW201219372A (en) 2012-05-16
AR083422A1 (es) 2013-02-21
CY1119007T1 (el) 2018-01-10
ZA201302746B (en) 2014-06-25
CA2814518A1 (en) 2012-04-19
EP3106163A1 (en) 2016-12-21
BR112013008983A2 (pt) 2016-07-05
KR20150002876A (ko) 2015-01-07
CA2814518C (en) 2016-09-20
CN103458690B (zh) 2016-03-16
AU2016204638B2 (en) 2018-06-07
NZ610012A (en) 2015-05-29
NZ707213A (en) 2016-12-23
HRP20170848T1 (hr) 2017-08-25
PL2637664T3 (pl) 2017-09-29
WO2012051559A2 (en) 2012-04-19
PT2637664T (pt) 2017-06-22
EP2637664A2 (en) 2013-09-18
JP2014506870A (ja) 2014-03-20
JP5806320B2 (ja) 2015-11-10
EP2637664A4 (en) 2014-09-10
KR20130069855A (ko) 2013-06-26
RS56135B1 (sr) 2017-10-31
SMT201700297T1 (it) 2017-07-18
US20160346280A1 (en) 2016-12-01
US20120269898A1 (en) 2012-10-25
TWI542580B (zh) 2016-07-21
HUE033346T2 (en) 2017-11-28
DK2637664T3 (en) 2017-06-19
SI2637664T1 (sl) 2017-07-31
AU2016204638A1 (en) 2016-08-04
AU2011315891A1 (en) 2013-05-23
LT2637664T (lt) 2017-11-10
EA201691759A1 (ru) 2017-05-31
EA026074B1 (ru) 2017-02-28
JP2015178528A (ja) 2015-10-08
US20140275098A1 (en) 2014-09-18
EA201390428A1 (ru) 2014-02-28

Similar Documents

Publication Publication Date Title
MX346730B (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
GT201400111A (es) Triazolopiridinas sustituidas
ECSP12012103A (es) Inhibidores de virus flaviviridae.
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
CO6480932A2 (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
AR077629A1 (es) Mimetico de smac
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CR20160527A (es) Derivados de carboxamida
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
AR088735A1 (es) Compuestos de tienopirimidina que son inhibidores de canal de potasio
UY33745A (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні

Legal Events

Date Code Title Description
FG Grant or registration